TY - JOUR
T1 - Progressive presynaptic dopaminergic deterioration in Huntington disease: a [123I]-FP-CIT SPECT two-year follow-up study.
AU - Gamez, Josep
AU - Lorenzo-Bosquet, Carles
AU - Cuberas-Borrós, Gemma
AU - Carmona, Francesc
AU - Badía, Mercedes
AU - Castilló, Joaquin
AU - Badía, Mercedes
AU - de Fabregues, Oriol
AU - Hernández-Vara, Jorge
AU - Castell-Conesa, Joan
PY - 2014/1/1
Y1 - 2014/1/1
N2 - To illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantitative analysis. The mean annual decline in [I]-FP-CIT uptake in caudate and putamen after 2 years of follow-up was 5.8% and 9.6%, respectively. Our findings suggest that [I]-FP-CIT SPECT is useful in investigating the progression of presynaptic dopaminergic degeneration in HD, and may be useful as a disease biomarker, providing an objective method for measuring the effectiveness of future neuroprotective therapies.
AB - To illustrate the potential of [I]-FP-CIT SPECT DaTSCAN® in investigating the progression of presynaptic dopaminergic degeneration in Huntington disease (HD), we performed a 2-year follow-up [I]-FP-CIT study on 4 HD patients, evaluating the SPECT imaging based on qualitative and semiquantitative analysis. The mean annual decline in [I]-FP-CIT uptake in caudate and putamen after 2 years of follow-up was 5.8% and 9.6%, respectively. Our findings suggest that [I]-FP-CIT SPECT is useful in investigating the progression of presynaptic dopaminergic degeneration in HD, and may be useful as a disease biomarker, providing an objective method for measuring the effectiveness of future neuroprotective therapies.
M3 - Article
SN - 1536-0229
VL - 39
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 3
ER -